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case report
MicroRNAs miR-146-5p and 
let-7f as prognostic tools for 
aggressive papillary thyroid 
carcinoma: a case report
MicroRNAs miR-146-5p e let-7f como ferramenta de prognóstico 
para o carcinoma papilífero de tiroide: relato de caso
Murilo Vieira Geraldo1*, Cesar Seigi Fuziwara1*, Celso Ubirajara 
Moretto Friguglieti2, Ricardo Borges Costa3, Marco Aurélio Vamondes 
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SUMMARY
Papillary thyroid cancer (PTC) is the most incident histotype of thyroid cancer. A certain frac-
tion of PTC cases (5%) are irresponsive to conventional treatment, and refractory to radioio-
dine therapy. The current prognostic factors for aggressiveness are mainly based on tumor 
size, the presence of lymph node metastasis, extrathyroidal invasion and, more recently, the 
presence of the BRAFT1799A mutation. MicroRNAs (miRNAs) have been described as promis-
ing molecular markers for cancer as their deregulation is observed in a wide range of tumors. 
Recent studies indicate that the over-expression of miR-146b-5p is associated with aggressive-
ness and BRAFT1799A mutation. Furthermore, down-regulation of let-7f is observed in several 
types of tumors, including PTC. In this study, we evaluated the miR146b-5p and let-7f status 
in a young male patient with aggressive, BRAFT1799A-positive papillary thyroid carcinoma, with 
extensive lymph node metastases and short-time recurrence. The analysis of miR-146b-5p and 
let-7f expression revealed a distinct pattern from a cohort of PTC patients, suggesting caution 
in evaluating miRNA expression data as molecular markers of PTC diagnosis and prognosis. Arq 
Bras Endocrinol Metab. 2012;56(8):552-7
SUMÁRIO
O carcinoma papilífero (PTC) é o histotipo mais prevalente de câncer de tiroide. Cerca de 5% 
dos casos são refratários ao tratamento convencional e à radioiodoterapia. Os fatores prognós-
ticos para agressividade mais utilizados atualmente são o tamanho do tumor, a presença de 
metástases linfonodais ao diagnóstico, a presença de invasão extratiroideana e, mais recen-
temente, a presença da mutação BRAFT1799A. A análise de perfil de expressão de microRNAs 
(miRNA) mostra que esses pequenos RNAs são marcadores moleculares promissores para o 
câncer, por apresentarem desregulação de sua expressão em uma ampla gama de tumores, 
includindo o PTC. Estudos recentes revelam a associação entre o aumento da expressão do 
miRNA e miR-146b-5p e a presença da mutação BRAFT1799A como um fator de pior prognóstico no 
PTC. Além disso, observa-se a diminuição da expressão de let-7f em diversos tipos de tumores, 
incluindo tumores tiroideanos. Neste relato de caso, realizamos a quantificação da expressão de 
miR-146b-5p e let-7f em um paciente jovem, de sexo masculino, apresentando PTC positivo para 
a mutação BRAFT1799A com extensas metástases linfonodais ao diagnóstico e recidiva precoce. 
A análise da expressão de miR-146b-5p e let-7f mostrou um padrão diferente do observado em 
um grupo de pacientes PTC, sugerindo a necessidade de cautela na interpretação da expressão 
de miRNAs como marcador molecular no diagnóstico e prognóstico de PTC. Arq Bras Endocrinol 
Metab. 2012;56(8):552-7 
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IntROdUCtIOn
Papillary thyroid cancer (PTC) is the most incident histotype of thyroid cancer, accounting for more 
than 80% of the 35,000 annual cases in the USA. To 
date, prediction of PTC outcome is mainly based on 
tumor size, gender, age of patient at time of diagnosis, 
presence lymph node metastasis, capsular invasion, and 
extra-thyroidal extension. Although most PTCs cases 
display overall good prognosis, a certain fraction of 
PTC cases (5%) are irresponsive to conventional treat-
ment and refractory to radioiodine therapy (1). Thus, 
a number of cases diagnosed as low-risk PTCs eventu-
ally recur locally and as lymph node metastases, lead-
ing to death (2), indicating the lack of current reliable 
outcome predictors. Indeed, no consensus has been 
achieved regarding the clinical application of molecular 
markers to predict the outcome of PTC patients (3). 
More recently, several studies suggest that the pres-
ence of mutation in BRAF oncogene is associated with 
a poor outcome due to frequent extra-thyroidal inva-
sion, recurrence, and lower survival rate (4-6). In this 
context, microRNAs (miRNAs) arise as interesting 
mar kers for cancer, as their deregulation affects innu-
merous cell processes, such as proliferation and apop-
tosis (7). MiRNAs negatively regulate protein levels by 
binding to 3’UTR of target mRNA and impairing pro-
tein translation (8). The potential of miRNAs as PTC 
molecular markers is highlighted, once their expres-
sion may be detected from formalin-fixed paraffin-em-
bedded (FFPE) tissue, fine needle aspiration cytology 
(FNAC), as well as serum samples (9).
Recent studies have explored the use of several 
miRNAs as cancer diagnostic tools (10). In the last 4 
years, several studies have demonstrated the potential 
of miRNAs in PTC diagnosis. Although miR-146b-5p 
is down-regulated in other types of cancer (11-13), this 
miRNA is highly overexpressed in PTCs (14,15), re-
liably distinguishing this type of cancer from follicular 
carcinoma (FTC), and from benign lesions (16,17). 
Moreover, Schwertheim and cols. have shown that a 
set of miRNAs that includes miR-146b-5p, distinguish-
es well-differentiated from undifferentiated thyroid 
tumors (18). Recent studies suggested that miRNA 
expression may be used as a thyroid cancer prognos-
tic tool. The expression levels of miR-146b-5p, along 
with other two miRNAs, miR-221 and -222, were sig-
nificantly higher in high-risk PTC patients who showed 
extra-thyroidal invasion (19). Moreover, among 
BRAFT1799A-positive PTCs, the aggressive subset pres-
ents high miR-146b-5p expression levels (20). Let-7f 
down-regulation was firstly described by Takamizawa 
and cols. (21) in lung cancer with poor prognosis, and 
rapidly arose as a promising cancer molecular marker 
(22). Although let-7f down-regulation has been de-
scribed in PTC, its usefulness as a diagnostic and prog-
nostic marker for PTC is uncertain.
In this study, we present a case report of a young 
male patient presenting an aggressive, BRAFT1799A-posi-
tive papillary thyroid carcinoma, displaying lymph node 
metastases at diagnosis and short-term recurrence after 
surgery, in whom we evaluated the expression pattern 
of the miRNAs miR-146b-5p and let-7f. 
SUBJECt And MEtHOdS
Case report
A 23-year-old caucasian male (named here ABC) with 
parents bearing Hashimoto’s thyroiditis, was submitted 
to a health checkup, and was diagnosed with hypothy-
roidism, positive for anti-TPO and anti-TG antibodies. 
At the ultrasound examination, calcified thyroid no-
dules of 12 mm and 8 mm were found at the isthmus 
and right lobe, respectively. The patient ABC also had 
lymphadenopathy of 33 mm, with calcification at level 
III of right side, and 9 mm at level III of left side. Fine 
needle aspiration citology (FNAC) pattern was com-
patible with PTC in the thyroid and in the right lateral 
lymph nodes, but not in the left side. The patient un-
derwent total thyroidectomy, and central compartment 
and right lateral lymph node dissection (levels II to V). 
Histopathological examination of the primary tumor 
confirmed the diagnosis of PTC (Figure 1A) with lym-
phatic invasion. Metastases were found in right lymph 
nodes at levels III (2 out of 7), IV (6 out of 6) (Figure 
1B), V (2 out of 3), and at the central compartment 
(3 out of 4). Neither vascular nor peri-neural invasion 
were detected. According to the American Joint Com-
mittee on Cancer Staging System, the tumor was classi-
fied as T3N1bM0 and MACIS score was 3.37 (23,24). 
Three months after surgery, the patient received 
200 mCi of 131I under Thyrogen® (Genzyme, Cam-
bridge, MA, USA) stimulation (TSH 140 μIU/mL). 
Thyroglobulin and anti-Tg antibodies levels were 
0.15 ng/mL and > 3,000 IU/mL, respectively. Eight 
months later, ultrasound examination showed lymph-
adenopathy at levels II, III and IV of the left side, the 
miRNA expression in an aggressive papillary thyroid cancer
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largest one with 19 mm, and elevated anti-Tg antibody 
levels (11,580 IU/m). FNAC revealed PTC and PET-
CT examination showed FDG uptake at level II. At the 
second surgery, lateral lymph node dissection was per-
formed on the left side (levels II to V). Histopathologi-
cal examination of lymph nodes revealed metastases at 
levels II (2 out 4), III (3 out 17), IV (2 out of 8) and 
V (9 out of 11). The patient received 200 mCi of 131I 
under Thyrogen® stimulation. Three months after the 
second surgery, radioiodine uptake was negative.
Patient population
Human PTC and non-tumor paired thyroid tissue sam-
ples were collected from patients, including ABC, after 
the informed consent was signed. This samples belong 
to the thyroid tumor tissue bank, approved by the ethi-
cal committee of the Institute of Biomedical Sciences 
(no. 1030/CEP), Universidade de Sao Paulo. Thyroid 
carcinomas were classified according to the last WHO 
classification (25). 
BRAF mutation detection
Genomic DNA was extracted from thyroid tissue us-
ing the salting-out protocol. Briefly, after digestion 
with proteinase K, protein was precipitated with 5 M 
NaCl, and DNA was isolated with isopropanol. Exon 
15 of BRAF, containing the hotspot T1799A muta-
tion, was amplified by PCR using specific primers (FW: 
5´- AAACTCTTCATAATGCTTGCTCTG-3’; RV: 
5’-GGCCAAAAATTTAATCAGTGGA-3’), and the 
product was purified in QIAquick® PCR purification 
miRNA expression in an aggressive papillary thyroid cancer
Figure 1. Histopathological slides of the resected differentiated PTC and lymph node metastasis. (A) Primary PTC. (B) Level IV lymph node metastasis. 
Hematoxylin-eosin, the black bar represents 100 µm. 
kit (Qiagen, Valencia, CA, USA). For direct sequenc-
ing reaction, the purified product was amplified using 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies), forward primer, and injected in multi-
capillary sequencer MegaBace1000 (GE Healthcare, 
Little Chalfont, UK) (26). The similarity of the result-
ing sequence was analyzed and confirmed using BLAST 
software (http://www.ncbi.nlm.nih.gov/BLAST/). 
MicroRnA expression
Excised tumor tissues were immediately stored in 
RNAlater®. Total RNA was extracted by phenol-
chloroform using TRIzol® reagent (LifeTechnologies, 
Carlsbad, CA, USA), according to the manufacturer’s 
instructions, and stored at -80oC. Detection of miRNAs 
miR-146b-5p, let-7f and RNU6B was performed 
using commercial kits (Life Technologies) according 
to the manufacturer’s specifications. Briefly, cDNA 
was synthesized from 10 ng of total RNA using 
specific pri mers in a stem-loop based technology with 
TaqMan MicroRNA Reverse Transcription Kit (Life 
Technologies). Expression was analyzed by qPCR using 
specific Taqman miRNA Assay (Life Technologies) 
and TaqMan® Master Mix no AmpErase® UNG (Life 
Technologies).
Statistical analysis
Quantification of miRNA expression is presented as 
mean ± S.E., and data were submitted to Student’s 
t-test to compare results between the two groups. 
Differen ces were considered significant at p < 0.05.
A B
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
555Arq Bras Endocrinol Metab. 2012;56/8
RESUltS
Analysis of genomic DNA from a set of PTC sam-
ples and paired contra-lateral thyroid tissue revealed 
BRAFT1799A mutation in 41% of patients, including the 
patient ABC (7/17).
MiR-146b-5p is substantially up-regulated in the 
cohort of PTCs from our tissue bank when compared 
with their matched contra-lateral samples, irrespective 
of their BRAFT1799A status (Figure 2A). Interestingly, 
both the primary tumor and metastatic tissue of ABC 
exhibited lower miR-146b-5p fold-change levels com-
pared with the cohort of PTC samples (Figure 2A), and 
no statistical differences compared with its paired nor-
mal thyroid tissue (P = 0.773). 
On the other hand, the BRAFT1799A tumors showed 
no significant changes in let-7f expression levels, while 
BRAF-wild type tumors exhibit increased let-7f lev-
els in comparison with matched contra-lateral thyroid 
tissue (Figure 2B). ABC primary tumor, which was 
BRAFT1799A-positive, exhibited a slight increase in let-7f 
levels (31%, P < 0.01) (Figure 2B). However, the meta-
static tissues, also positive for BRAFT1799A-, displayed 
decreased let-7f levels (Fig 3B).
in distinguishing malignant from benign tumors, and 
that different thyroid cancer histotypes display distinct 
miRNA expression (17,27). However, in patient ABC, 
the expression pattern of miR-146b-5p and let-7f levels 
could not be associated with aggressiveness and poor 
prognosis, as previously described in the literature. 
It is not clear whether the overexpression of miR-
146b-5p is associated to BRAFT1799A status. While initial 
studies showed no correlation between this miRNA and 
oncogenic activation (9), recent studies have demon-
strated a positive correlation between the overexpres-
sion of miR-146b-5p and aggressive BRAFT1799A tumors 
(19). Moreover, in the literature, high expression of 
miR-146b-5p is associated with BRAF-mutated tumors 
that display more aggressive phenotypes (20). Con-
versely, our cohort of patients did not show any corre-
lation regarding BRAF status and miR-146b-5p expres-
sion. MiR-146b-5p is associated with the deregulation 
of NFκB and TGFβ pathways, while the blockage of 
miR-146b-5p action restores TGFβ signal transduction 
in thyroid cells in vitro (28). Non-thyroid tumors fre-
quently exhibit reduced levels of miR-146b-5p (11,29). 
We have previously shown that activation of MAPkinase 
pathway in normal thyroid cells increases miR-146b-5p 
levels in vitro (28). Therefore, the overexpression of 
miR-146b-5p, only observed in thyroid tumors, could 
be related with a thyroid-specific oncogenic activation, 
which might include the MAPK pathway. 
The association between BRAFT1799A and let-7f ex-
pression also remains poorly understood. Classically, 
the main target of let-7 is RAS oncogene, an impor-
tant transducer for the MAPK pathway. Interestingly, a 
functional study revealed that the reinforced expression 
of let-7f in a PTC cell line blocks ERK phosphoryla-
tion without affecting RAS protein levels (30). On the 
other hand, we have previously shown that activation 
of RET/PTC rearrangement in rat normal thyroid cell 
line, but not of BRAF mutation, decreases let-7f levels. 
In our cohort of patients, BRAFT1799A-positive tumors 
showed no change in let-7f levels, in comparison with 
contra-lateral thyroid tissue, while BRAFwild type tu-
mors displayed increased levels of this miRNA. Inter-
estingly, the patient ABC, which was BRAFT1799A-posi-
tive, showed slightly increased let-7f expression, even 
though his metastatic tissue, also BRAFT1799A-positive, 
showed decreased levels of let-7f. Little is known about 
the targets regulated by let-7f in PTC. Different mRNA 
targets might be regulated by let-7f to promote matrix 
remodeling, vascular infiltration, and the colonization 
miRNA expression in an aggressive papillary thyroid cancer
Figure 2. MiR-146b and let-7f levels in PTC samples. Expression of miR-
146b-5p (A) and let-7f (B) in PTC samples in comparison with contra-
lateral thyroid tissue. Values are represented as mean ± SE of expression 
fold-change matched to contra-lateral thyroid tissue. RNU6B gene 
expression was used as an internal control. ABC, patient ABC; Meta IV, 
lymph node metastasis at level IV; Meta VI, lymph node metastasis at level 
VI. (*) P < 0.01, against matched thyroid contra-lateral tissue.
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dISCUSSIOn
MiRNAs have been described as markers for diagno-
sis and prognosis, once their expression pattern may 
classify tumor types and aggressiveness accurately 
(10). Recent studies showed that molecular screening 
of miRNA expression in thyroid tumors is important 
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of the metastatic site. Functional studies are needed to 
elucidate whether the loss of let-7f by primary tumor 
is implicated in thyroid tumor progression and what is 
the clinical significance of this data. 
To date, clinical and histological features, such as 
age, gender, extra-thyroidal invasion, and, vascular in-
vasion, histotype, and more recently, BRAFT1799A status, 
are still the indicated parameters for accurate PTC out-
come prediction. Furthermore, recent lines of evidence 
have shown that the number of lymph node metasta-
ses is also important to predict the patient’s outcome, 
and may be used as an independent prognostic factor 
for aggressiveness (31), which corroborate the clinical 
characteristics of patient ABC. 
This case showed to be interesting because of the 
discordance of two widely studied PTC miRNA mar kers 
in this index patient and our cohort of patients. Our data 
indicate that the expression pattern of miR-146b-5p and 
let-7f genes may not reproduce the clinical features of 
the tumor, clearly illustrating that outcome prediction 
based on the analysis of the expression of a single or few 
miRNA genes should be viewed with caution. 
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